31. The use of claim 29, wherein the antigen binding fragment is administered by intravenous administration or by subcutaneous administration.

32. The use of claim 30, wherein the autoimmune disease is multiple sclerosis.

3332. The use of claim 30, wherein the autoimmune disease is rheumatoid arthritis.

3433. The use of claim 3332, wherein the patient is suffering from moderate to severe rheumatoid arthritis and has failed treatment with at least one disease-modifying antirheumatic drug.

3534. The use of claim 3332, wherein the patient is to be administered with a second therapeutic agent.

3635. The use of claim 3534, wherein the second therapeutic agent is an immunosuppressive agent.

3736. The use of claim 3635, wherein the immunosuppressive agent is methotrexate.

3837. The use of claim 3332, wherein the antigen binding fragment is to be administered at a dosage selected from 2x10mg, 2x50mg, 2x 200mg, and 2x500mg.

3938. The use of claim 3837, wherein the antigen binding fragment is to be administered by intravenous infusion.

4039. Use of the antigen binding fragment of any one of claims 1-3 in the manufacture of a medicament for treating rheumatoid arthritis (RA) in a human subject, wherein the antigen binding fragment is to be administered at a dosage selected from the group consisting of 2x10 mg, 2x50 mg, 2x200 mg, and 2x500 mg.

4140. The use of claim 4039, wherein the rheumatoid arthritis is moderate rheumatoid arthritis to severe rheumatoid arthritis.